Open AccessTanshinone for polycystic ovary syndrome
Author(s) -
Yijiao Yang,
Yue Xia,
Xia Peng,
Jiani Xie,
Honglin Liu,
Xinyan Ni
Publication year - 2021
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000024287
Subject(s) - polycystic ovary , medicine , cochrane library , cinahl , randomized controlled trial , medline , meta analysis , gynecology , psychiatry , insulin resistance , political science , insulin , psychological intervention , law
Backgrounds: Polycystic ovary syndrome (PCOS) constitutes an endocrine and metabolic disorder characterized by hyperandrogenemia, ovulation disorders, and polycystic ovary. Existing therapy is low efficacy and has significant side effects. In traditional Chinese medicine, tanshinone was used for PCOS women. Here, we will investigate the safety, as well as the efficacy of tanshinone in treating polycystic ovary syndrome. Methods: Two researchers will independently research eligible randomized controlled trials in 6 repositories: PubMed, CINAHL, Web of Science, EMBASE, China National Knowledge Infrastructure (CNKI), as well as Cochrane Library, from their onset to present. The languages will constitute either English or Chinese, and we will carry out article selection, data mining, and conduct an evaluation of the risk of bias by the Cochrane tool of risk of bias. All analyses will be conducted by using the Cochrane Review Manager software (RevMan 5.3). Results and conclusion: This study will provide the latest research evidence on the efficacy, as well as safety of tanshinone for PCOS patients. Registration number: INPLASY2020100017